Skip to main content
Premium Trial:

Request an Annual Quote

NCI Puts SNP Detectors to the Test

NEW YORK, Sept 21 – Nanogen (Nasdaq: NGEN) announced Thursday that the US National Cancer Institute had purchased its NanoChip system for the full list price of   $150,000, but the institute’s Advanced Technology Center said the deal does not signal a preference for one technology over another.

“We use multiple technologies” for SNP detection, said Stephen Chanock of the NCI’s Advanced Technology Center, including Sequenom’s (Nasdaq: SQNM) MassArray system, Applied Biosystems’ (NYSE: PEB) Snapshot and TaqMan, and classical molecular biology methods.

“We need to see these [technologies] head to head,” he said. “The last thing I want to do is rely only upon the commercial companies’ data and their public releases.”

The center is collecting data and comparing the various methods. It plans to publish the results in an unnamed scientific journal within a few months.

The advantage of one technology over the other is not straightforward and often depends on what you are studying, Chanock said.

“There are strengths and weaknesses to each that are applicable to different circumstances,” he said.

Like different classes of cars, “they accommodate different budgets and different needs,” said Chanock. “I can’t say right now that one is the Cadillac and one is the Volkswagen."  

Bud Bromley, senior vice president of sales and marketing at Nanogen, agreed that the NanoChip system is not the best choice for every situation.

“If you’re looking for a few SNPs in millions of people, well, that’s probably a screening application that would be better on a Sequenom machine,” he said. “On the other hand, if you already know what the SNP is and you want a very accurate answer for a patient…that’s the application for our system.”

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.